Blueprint Medicines Corporation’s move into the competitive CDK2 inhibitor space has hit an obstacle as the US Food and Drug Administration has slapped a partial clinical hold on its Phase I/II VELA trial of BLU-222 due to some patients experiencing visual adverse events. But the company anticipates resolving the hold and remains on track to present dose-escalation data in the first half of 2023.
Blueprint announced the hold on 10 February, two days after it was notified by the FDA, and said the events...